Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs. Glibenclamide on Endothelial Function in T2DM
NCT02145611Phase 4Completed
- Start
- Jul 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Reactive Hyperemia Index at 12 weeks and Central Blood Pressure at 12 weeks. Started Jul 2013; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02145611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145611.